Form Bio

Name

Form Bio

Legal name

Form Bio, Inc.

Website

https://formbio.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Genetic Medicine Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Genetic medicine platform
• Genome engineering services
• AAV vector design
• Cell gene therapy
• Codon optimization AI

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Platform-as-a-Service Subscription: Form Bio provides access to a platform-as-a-service that includes datasets, analytic workflows, algorithms, cloud-computing infrastructure, and scientific support. Access requires registration for user accounts and payment of applicable fees.
2. FormManufacturing Services: AI-driven design optimization and genomic characterization services for genetic medicine manufacturing, combining FormSightAI and FormBatchQC for drug substance and manufacturing intelligence.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Form Bio provides an AI-driven platform for genetic medicine development and genome engineering, anchored by the FormManufacturing end-to-end system that combines the FormSightAI in silico vector design screening tool with the FormBatchQC lot-level genomic characterization service. The company sells platform subscriptions, codon optimization powered by the proprietary FORMsightAI model, and professional services for genome assembly, genome integrity analysis, protein engineering, and multiomic analysis to biotech and pharmaceutical companies developing cell and gene therapies.

Product overview

Form Bio is an AI-driven genetic medicine and genome engineering company that spun out from Colossal Biosciences in 2022. The company offers a comprehensive platform centered around FormManufacturing, which integrates AI-driven design (FormSightAI) with genomic characterization (FormBatchQC) to de-risk cell and gene therapy manufacturing. Additional offerings include codon optimization powered by the proprietary FORMsightAI model, genome assembly, genome integrity analysis, genome engineering, and protein engineering services. The platform provides solutions across drug substance insights, capsid analysis, bioinformatics analysis, gene editing, AI model development, and manufacturing intelligence for genetic medicine developers.

Differentiator

Problem solved

Functional benefit

Products and services

• FormManufacturing End-to-end platform that integrates AI-driven design optimization with deep genomic characterization to improve genetic medicine safety, efficacy, and manufacturability from discovery to commercial scale for biotech and pharmaceutical developers.
• FormSightAI

Quantifiable outcome

• 40% of IND submissions are delayed by CMC gaps
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and flagship.

• Cure Rare DiseasecoreStrategic or Co-development Partner · 30 October 2025Partnership leverages AI-powered genome design to optimize AAV constructs, accelerate lead candidate selection, and improve drug substance manufacturability for rare and ultra-rare neuromuscular diseases including DMD program.
• Weill Cornell MedicinecoreStrategic or Co-development Partner · 30 October 2025Strategic collaboration to advance gene editing therapy for Alzheimer's disease. AI-powered vector design and preclinical validation mark first step in multi-phase program aimed at accelerating path from discovery to clinical assessment.
• Azenta Life SciencescoreStrategic or Co-development Partner · 13 May 2025Strategic partnership to advance AAV gene therapy development with integrated solution aimed at reducing time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.
• PacBiocoreStrategic or Co-development Partner · 27 June 2024Collaboration to launch new resources and expert working group aimed at advancing and unifying the AAV industry. Includes AAV Resource Hub and working group to introduce essential tools for AAV development professionals.
• Google CloudcoreTechnology or Integration · 22 April 2024Form Bio harnesses Google Cloud for multiomic analysis platform built on Google Cloud's Multiomics Suite. Google Cloud's powerful AI models for healthcare and life sciences research available as point-and-click workflows via Form Bio's bioinformatics platform on Google Cloud Marketplace.
• Ginkgo BioworkscoreStrategic or Co-development Partner · 28 February 2024Partnership to develop industry-leading solutions for AAV gene therapy design and development. Combined solution addresses critical hurdles in bringing gene therapy products to IND through collaborative design and development efforts.
• Colossal BiosciencesflagshipStrategic or Co-development PartnerForm Bio is the first spinout from Colossal Biosciences (2022), which established the company's foundational multi-species genome engineering technology. Colossal's leadership including George Church, PhD serves as advisors. Colossal is Form Bio's trusted partner for genome engineering programs.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Benchling: Benchling is a widely adopted cloud-based lab informatics platform serving biotech R&D, comparable to Form Bio's multiomic and bioinformatics analysis offering but as a horizontal platform rather than a genetic-medicine-specialized AI tool.
• Schrödinger: Schrödinger is a larger computational drug discovery platform offering physics-based and ML tools across multiple modalities, comparable to Form Bio's AI platform approach but with a broader, modality-agnostic portfolio.

Direct peers

• BigHat Biosciences: BigHat Biosciences applies AI/ML to antibody design and engineering, comparable to Form Bio's AI-driven sequence optimization and protein engineering capabilities for therapeutic development.
• Insitro: Insitro applies machine learning to drug discovery and development across multiple therapeutic modalities, comparable to Form Bio's AI-driven platform approach for genetic medicine design and characterization.
• AbCellera Biologics: AbCellera combines AI/ML with high-throughput antibody discovery, sharing the AI-augmented biologic engineering and platform-services business model that Form Bio applies to genetic medicines.
• Recursion Pharmaceuticals: Recursion operates a scaled AI-driven drug discovery platform combining high-throughput biology with machine learning, comparable to Form Bio's integrated AI plus wet-lab genetic medicine platform model.
• Generate Biomedicines: Generate Biomedicines is an AI-first generative biology company designing novel protein therapeutics using machine learning, directly comparable to Form Bio's AI-driven protein and genetic sequence design capabilities.
• Tessera Therapeutics: Tessera is a genetic medicines company developing gene writing technologies, directly comparable to Form Bio's genetic medicine and genome engineering focus area.
• Cradle Bio: Cradle uses generative AI and ML for protein engineering and design, directly comparable to Form Bio's AI-driven protein engineering offering under its protein engineering portfolio.
• Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology and cell engineering platform, directly comparable to Form Bio's genome engineering capabilities and an existing strategic partner for AAV gene therapy development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/form_bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Form Bio